Long-term follow-up of gene therapy for hemophilia A or B
Follows people with hemophilia A or B after earlier gene therapy treatment.
Plain-language title generated from the registry record
Registry title: Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Key facts
- Where
- Athens, GreeceSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with hemophilia A or B who already received giroctocogene fitelparvovec or fidanacogene elaparvovec in an earlier Pfizer-sponsored study. It follows their long-term safety and results.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Hemophilia A or hemophilia B
- Earlier treatment
- Must have received giroctocogene fitelparvovec or fidanacogene elaparvovec in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003).
Read by machine on 12 November 2026.
Where in Greece
- General Hospital of Athens "Laiko"Athens, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Pfizer
- Trial code
- NCT05568719
- Record updated
- 7 October 2026
- Original description
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.Read full original descriptionShow less
A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Inclusion: -Only participants who received investigational giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible.
Exclusion: -None.